OAKLAND, N.J. — Findings from a recent study are highlighting the clinical efficacy of AEYE Health and Topcon Healthcare’s artificial intelligence (AI) solutions for autonomous diabetic retinopathy screening. Together, Topcon’s NW500 non-mydriatic retinal camera and AEYE’s Diagnostic Screening (AEYE-DS) set a new standard for accessible, on-the-spot patient care.
AEYE-DS AI technology, in conjunction with the Topcon NW500, demonstrated unparalleled results, including:
- Exceptional clinical diagnostic efficacy: 92% sensitivity and 90% specificity
- Unprecedented imageability: 100% of patients received diagnostic results, with >99% successfully imaged on the first attempt without dilation
AEYE-DS is already FDA-cleared for use with Topcon’s TRC-NW400 and can be accessed through the Harmony digital health platform. AEYE Health is seeking additional clearance for its autonomous screening solution in combination with the Topcon NW500. AEYE-DS is the only approved autonomous AI solution that requires a single image per eye and, with the NW500, does not require dilation, therefore significantly improving the time to screen patients to under one minute.
This clinical data highlights the exceptional efficacy and unprecedented usability of the Topcon NW500 with AEYE-DS AI technology. The powerful synergy of this solution, including Harmony, makes it ideal for a wide range of clinical settings, enabling on-the-spot, efficient, and accurate diagnostic screening and streamlining referrals for timely treatment.
“This is a great day for blindness prevention, as our partnership with Topcon Healthcare continues to advance diabetic retinopathy screening using AI,” said Zack Dvey-Aharon, PhD, CEO of AEYE Health. “With Topcon’s NW500, we were able to achieve 100% imageability and virtually 100% success rate on the first attempt without dilation. This means all patients can be screened on the spot, ensuring no one is left out of this critical diagnostic opportunity. This amazing advancement will significantly increase adoption of AI screening in the U.S. and around the world.”
“To successfully scale DR screening for all patients, robotic and high-quality imaging combined with a robust AI algorithm is essential,” said Ali Tafreshi, CEO & President of Topcon Healthcare, Inc. “The NW500 with AEYE-DS will empower primary care providers to improve patient outcomes and enhance adherence to diabetic retinopathy screenings. It is another significant milestone in delivering Healthcare from the Eye.”
Author
